The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Absence of Growth Retardation in Children With Perennial Allergic Rhinitis After One Year of Treatment With Mometasone Furoate Aqueous Nasal Spray
Abstract
Objective.: Intranasal corticosteroids are used widely for the treatment of allergic rhinitis because they are effective and well tolerated. However, their potential to suppress growth of pediatric subjects with allergic rhinitis continues to be a concern, particularly in light of reports of growth suppression after treatment with intranasal beclomethasone dipropionate or intranasal budesonide (see the article by Skoner et al in this month's issue). A 1-year study of prepubertal patients between 3 and 9 years of age with perennial allergic rhinitis was conducted to assess the effects on growth of mometasone furoate aqueous nasal spray (MFNS), a new once-daily (QD) intranasal corticosteroid with negligible bioavailability. Methods.: This was a randomized, placebo-controlled, double-blind, multicenter study. Ninety-eight subjects were randomized to treatment with either MFNS 100 μg QD or placebo for 1 year. Each subject's height was required to be between the 5th and 95th percentile at baseline, and skeletal age at screening was required to be within 2 years of chronological age, as determined by left wrist x-rays. Washout periods for medications that affect either childhood growth or allergic rhinitis symptoms were established based on estimated period of effect, and these medications were prohibited during the study. However, short courses of either oral prednisone lasting no longer than 7 days or low-potency topical dermatologic corticosteroids lasting no longer than 10 days were permitted if necessary. Height was measured with a calibrated stadiometer at baseline and at 4, 8, 12, 26, 39, and 52 weeks, and the primary safety variable was the change in standing height. The rate of growth was also calculated for each subject as the slope (linear regression) of the change in height from baseline using data from all visits of subjects who had at least 2 visits. Hypothalamic-pituitary-adrenocortical- (HPA)-axis function was assessed via cosyntropin stimulation testing at baseline and at 26 and 52 weeks. All analyses were based on all randomized subjects (intent-to-treat principle). The change from baseline in standing height was analyzed by a 2-way analysis of variance that extracted sources of variation attributable to treatment, center, and treatment-by-center interaction. Results.: Demographic characteristics were similar at baseline. Eighty-two subjects completed the study (42 in the MFNS group and 40 in the placebo group), and 93% of subjects achieved at least 80% compliance with therapy. After 1 year of treatment, no suppression of growth was seen in subjects treated with MFNS, and mean standing heights were similar for both treatment groups at all time points. For the primary safety variable (change in height from baseline), both treatment groups were similar at all time points except for weeks 8 and 52. Subjects treated with MFNS had a slightly greater mean increase in height than subjects treated with placebo at these time points: the change in height was 6.95 cm versus 6.35 cm at the 1-year time point. However, the rate of growth (.018 cm/day) averaged for all time points over the course of the study was similar for both treatment groups. Additional analyses found that MFNS did not retard growth in any sex or age subgroup of subjects. The use of exogenous corticosteroids other than the study drug was also similar among the 2 treatment groups. Results from cosyntropin stimulation testing confirmed the absence of systemic effects of MFNS. The change from baseline in the difference between prestimulation and poststimulation levels was similar for both treatment groups after 1 year of treatment, with no evidence of HPA-axis suppression in MFNS-treated subjects at any time point. Incidences of treatment-related adverse events were similar for both treatment groups, with 16% of MFNS-treated subjects reporting adverse events, compared with 22% of placebo-treated subjects. Conclusions.: In summary, 1 year of treatment with MFNS 100 μg QD was found to be well tolerated, with no evidence of retardation of growth or suppression of HPA-axis function in perennial allergic rhinitis subjects as young as 3 years of age. These findings may be particularly relevant for children with co-morbid atopic disorders, such as asthma and eczema. Such patients may be treated concurrently with inhaled and/or dermatologic corticosteroids, thereby increasing the risk of systemic adverse events, including growth suppression. The absence of systemic adverse events found in this study, combined with the established efficacy and safety profile of MFNS in children, indicates that it may be an appropriate therapy for children as young as 3 years of age.3,4
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1994) · Ghent University Academic Bibliography (Ghent University) · Cited by 335
Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids
Lipworth, B. J., & Seckl, J. R. (1997) · Thorax · doi:10.1136/thx.52.5.476 · Cited by 144
Graft, D. F., Aaronson, D. W., Chervinsky, P., Kaiser, H. B., Melamed, J., Pedinoff, A., Rosen, J. P., Schenkel, E. J., Vandewalker, M. L., KEIM, A., et al. (1996) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(96)70119-7 · Cited by 116
Self-citationOnrust, S. V., & Lamb, H. M. (1998) · Drugs · doi:10.2165/00003495-199856040-00018 · Cited by 113
Wolthers, O. D., & Pedersen, S. (1993) · Acta Paediatrica · doi:10.1111/j.1651-2227.1993.tb18030.x · Cited by 110
Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children
Brannan, M. D., Herron, J. M., & Affrime, M. B. (1997) · Clinical Therapeutics · doi:10.1016/s0149-2918(97)80008-2 · Cited by 107
Hébert, J., Nolop, K. B., & Lutsky, B. N. (1996) · Allergy · doi:10.1111/j.1398-9995.1996.tb04670.x · Cited by 100
Self-citationInfluence of inhaled corticosteroids on growth: a pediatric endocrinologist's perspective
Allen, D. (1998) · Acta Paediatrica · doi:10.1111/j.1651-2227.1998.tb00960.x · Cited by 79
Allergic and non-allergic rhinitis.
González Diez, M. (2000) · PubMed · Cited by 79
Wolthers, O. D., & Pedersen, S. S. (1994) · Allergy · doi:10.1111/j.1398-9995.1994.tb00807.x · Cited by 77
Cited by
European Position Paper on Rhinosinusitis and Nasal Polyps 2020
Fokkens, W. J., Lund, V. J., Hopkins, C., Hellings, P. W., Kern, R., Reitsma, S., Toppila-Salmi, S., Bernal-Sprekelsen, M., Mullol, J., Alobid, I., et al. (2020) · Rhinology journal · doi:10.4193/rhin20.600 · Cited by 5,882
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*
Bousquet, J., Khaltaev, N., Cruz, A. A., Denburg, J., Fokkens, W. J., Togias, A., Zuberbier, T., Baena‐Cagnani, C. E., Canonica, G. W., Van Weel, C., et al. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01620.x · Cited by 4,729
Allergic Rhinitis and Its Impact on Asthma
Bousquet, J., van Cauwenberge, P., & Khaltaev, N. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.118891 · Cited by 3,588
Fokkens, W. J., Lund, V. J., Mullol, J., Bachert, C., Alobid, I., Baroody, F., Cohen, N., Cervin, A., Douglas, R., Gevaert, P., et al. (2012) · Rhinology journal · doi:10.4193/rhino12.000 · Cited by 2,387
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision
Brożek, J. L., Bousquet, J., Baena-Cagnani, C. E., Bonini, S., Canonica, G. W., Casale, T. B., van Wijk, R. G., Ohta, K., Zuberbier, T., & Schünemann, H. J. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.06.047 · Cited by 1,813
The diagnosis and management of rhinitis: An updated practice parameter
WALLACE, D., DYKEWICZ, M., BERNSTEIN, D., BLESSINGMOORE, J., COX, L., KHAN, D., LANG, D., NICKLAS, R., OPPENHEIMER, J., & PORTNOY, J. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.06.003 · Cited by 1,096
“Growth suppression, assessed by stadiometer height measurement, was detected in children with perennial allergic rhinitis treated with intranasal beclomethasone dipropionate for 1 year at twice the usually recommended dose.(409) Similar studies with intranasal fluticasone propionate, mometasone furoate, and budesonide…”
BackgroundClinical Practice Guideline: Allergic Rhinitis
Seidman, M. D., Gurgel, R. K., Lin, S. Y., Schwartz, S. R., Baroody, F. M., Bonner, J. R., Dawson, D. E., Dykewicz, M. S., Hackell, J. M., Han, J. K., et al. (2015) · Otolaryngology–Head and Neck Surgery · doi:10.1177/0194599814561600 · Cited by 671
“In the yearlong studies using stadiometry, intranasal beclomethasone dipropionate, at twice the recommended daily dosage, resulted in growth suppression, but fluticasone propionate and mometasone furoate showed no effects on growth compared with placebo.(197,198) In a small, nonrandomized, open-label study, children w…”
BackgroundExecutive Summary of EPOS 2020 Including Integrated Care Pathways
Fokkens, W. J., Lund, V. J., Hopkins, C., Hellings, P. W., Kern, R., Reitsma, S., Toppila-Salmi, S., Bernal-Sprekelsen, M., & Mullol, J. (2020) · Rhinology journal · doi:10.4193/rhin20.601 · Cited by 533
Dykewicz, M. S., & Hamilos, D. L. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.12.989 · Cited by 504
Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology
Roberts, G., Xatzipsalti, M., Borrego, L. M., Custovic, A., Halken, S., Hellings, P. W., Papadopoulos, N. G., Rotiroti, G., Scadding, G., Timmermans, F., et al. (2013) · Allergy · doi:10.1111/all.12235 · Cited by 416
BSACI guidelines for the management of allergic and non‐allergic rhinitis
Scadding, G. K., Durham, S. R., Mirakian, R., Jones, N. S., Leech, S. C., Farooque, S., Ryan, D., Walker, S. M., Clark, A. T., Dixon, T. A., et al. (2008) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2007.02888.x · Cited by 375
Scadding, G. K., Kariyawasam, H. H., Scadding, G., Mirakian, R., Buckley, R. J., Dixon, T., Durham, S. R., Farooque, S., Jones, N., Leech, S., et al. (2017) · Clinical & Experimental Allergy · doi:10.1111/cea.12953 · Cited by 359
Executive Summary of the Workshop Report 7–10 December 1999, Geneva, Switzerland
Bousquet, J., Van Cauwenberge, P., & Khaltaev, N. (2002) · Allergy · doi:10.1034/j.1398-9995.2002.23625.x · Cited by 298
Small, P., Keith, P. K., & Kim, H. (2018) · Allergy, Asthma & Clinical Immunology · doi:10.1186/s13223-018-0280-7 · Cited by 272
Economic impact and quality-of-life burden of allergic rhinitis
Schoenwetter, W. F., Dupclay, L., Appajosyula, S., Botteman, M. F., & Pashos, C. L. (2004) · Current Medical Research and Opinion · doi:10.1185/030079903125003053 · Cited by 256
Kakli, H. A., & Riley, T. D. (2016) · Primary Care: Clinics in Office Practice · doi:10.1016/j.pop.2016.04.009 · Cited by 200
The Pathophysiology, Diagnosis and Treatment of Allergic Rhinitis
Min, Y.-G. (2010) · Allergy, Asthma and Immunology Research · doi:10.4168/aair.2010.2.2.65 · Cited by 188
Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report
Papadopoulos, N. G., Bernstein, J. A., Demoly, P., Dykewicz, M., Fokkens, W., Hellings, P. W., Peters, A. T., Rondon, C., Togias, A., & Cox, L. S. (2015) · Allergy · doi:10.1111/all.12573 · Cited by 182
Influences of Allergic Rhinitis on Sleep
Ferguson, B. J. (2004) · Otolaryngology–Head and Neck Surgery · doi:10.1016/j.otohns.2004.02.001 · Cited by 124
Corticosteroid Treatment in Chronic Rhinosinusitis: The Possibilities and the Limits
Mullol, J., Obando, A., Pujols, L., & Alobid, I. (2009) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2009.07.001 · Cited by 105
Non‐surgical treatment of adenoidal hypertrophy: The role of treating IgE‐mediated inflammation
Scadding, G. (2010) · Pediatric Allergy and Immunology · doi:10.1111/j.1399-3038.2010.01012.x · Cited by 72
Juel-Berg, N., Darling, P., Bolvig, J., Foss-Skiftesvik, M. H., Halken, S., Winther, L., Hansen, K. S., Askjaer, N., Heegaard, S., Madsen, A. R., et al. (2017) · American Journal of Rhinology & Allergy · doi:10.2500/ajra.2016.30.4397 · Cited by 70
Williamson, I., Benge, S., Barton, S., Petrou, S., Letley, L., Fasey, N., Haggard, M., & Little, P. (2009) · BMJ · doi:10.1136/bmj.b4984 · Cited by 57
Intranasal corticosteroids: topical potency, systemic activity and therapeutic index
Daley-Yates, P. T., Larenas-Linnemann, D., Bhargave, C., & Verma, M. (2021) · Journal of Asthma and Allergy · doi:10.2147/jaa.s321332 · Cited by 49
Metadata
- Authors
- Schenkel, E. J., Skoner, D. P., Bronsky, E. A., Miller, S. D., Pearlman, D. S., Rooklin, A., Rosen, J. P., Ruff, M. E., Vandewalker, M. L., Wanderer, A., Damaraju, C. V., Nolop, K. B., & Mesarina-Wicki, B.
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2000-02-01
- Volume
- 105
- Issue
- 2
- Pages
- e22-e22
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2141229428
- Cited by
- 354
- References
- 14
- FWCI
- 7.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.